CL2012003011A1 - Comprimido de desintegracion por via oral que contiene un 1-30 % de acarbosa, un 40-90 % de un vehiculo soluble en agua y un 1-50 % de un vehiculo soluble en agua, para el tratamiento de diabetes mellitus; y procedimiento para preparar comprimidos de desintegracion oral que contienen acarbosa. - Google Patents
Comprimido de desintegracion por via oral que contiene un 1-30 % de acarbosa, un 40-90 % de un vehiculo soluble en agua y un 1-50 % de un vehiculo soluble en agua, para el tratamiento de diabetes mellitus; y procedimiento para preparar comprimidos de desintegracion oral que contienen acarbosa.Info
- Publication number
- CL2012003011A1 CL2012003011A1 CL2012003011A CL2012003011A CL2012003011A1 CL 2012003011 A1 CL2012003011 A1 CL 2012003011A1 CL 2012003011 A CL2012003011 A CL 2012003011A CL 2012003011 A CL2012003011 A CL 2012003011A CL 2012003011 A1 CL2012003011 A1 CL 2012003011A1
- Authority
- CL
- Chile
- Prior art keywords
- acarbose
- water soluble
- oral disintegration
- soluble vehicle
- procedure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Comprimido de desintegración por vía oral que contiene un 1-30 % de acarbosa, un 40-90 % de un vehículo soluble en agua y un 1-50 % de un vehículo soluble en agua, para el tratamiento de diabetes mellitus; y procedimiento para preparar comprimidos de desintegración oral que contienen acarbosa.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10161114 | 2010-04-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2012003011A1 true CL2012003011A1 (es) | 2013-04-19 |
Family
ID=44344015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2012003011A CL2012003011A1 (es) | 2010-04-27 | 2012-10-26 | Comprimido de desintegracion por via oral que contiene un 1-30 % de acarbosa, un 40-90 % de un vehiculo soluble en agua y un 1-50 % de un vehiculo soluble en agua, para el tratamiento de diabetes mellitus; y procedimiento para preparar comprimidos de desintegracion oral que contienen acarbosa. |
Country Status (26)
Country | Link |
---|---|
US (1) | US20130131003A1 (es) |
EP (1) | EP2563329B1 (es) |
JP (1) | JP5944378B2 (es) |
KR (1) | KR101788350B1 (es) |
CN (2) | CN106924199A (es) |
AU (1) | AU2011247642C1 (es) |
BR (1) | BR112012027303A2 (es) |
CA (1) | CA2797365A1 (es) |
CL (1) | CL2012003011A1 (es) |
CO (1) | CO6640213A2 (es) |
CR (1) | CR20120548A (es) |
CU (1) | CU20120152A7 (es) |
DO (1) | DOP2012000277A (es) |
EC (1) | ECSP12012279A (es) |
ES (1) | ES2623025T3 (es) |
GT (1) | GT201200290A (es) |
IL (1) | IL222368B (es) |
MX (1) | MX348865B (es) |
MY (1) | MY179724A (es) |
NZ (1) | NZ603199A (es) |
PE (1) | PE20130403A1 (es) |
SG (2) | SG184851A1 (es) |
SI (1) | SI2563329T1 (es) |
TW (1) | TWI556823B (es) |
UA (1) | UA111155C2 (es) |
WO (1) | WO2011134962A2 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR201100150A2 (tr) * | 2011-01-06 | 2012-07-23 | Bi̇lgi̇ç Mahmut | Suda çözünür dozaj formları |
WO2013115741A1 (en) * | 2012-01-31 | 2013-08-08 | Mahmut Bilgic | Pharmaceutical compositions comprising alpha-glucosidase inhibitor |
WO2013115738A1 (en) * | 2012-01-31 | 2013-08-08 | Mahmut Bilgic | Micronized acarbose |
CA2922849A1 (en) | 2012-08-31 | 2014-03-06 | Ixchel Pharma, Llc | Agents useful for treating obesity, diabetes and related disorders |
CN104013590A (zh) * | 2014-05-09 | 2014-09-03 | 万特制药(海南)有限公司 | 一种含阿卡波糖的药物组合物及其制备方法 |
SI3233066T1 (sl) * | 2014-12-17 | 2022-02-28 | Empros Pharma AB, c/o BTR, | Sestavek s prirejenim sproščanjem, ki vsebuje orlistat in akarbozo za zdravljenje prekomerne teže in povezanih metaboličnih motenj |
CN105213341A (zh) * | 2015-10-29 | 2016-01-06 | 无锡福祈制药有限公司 | 一种阿卡波糖片及其制备方法 |
CN113081984B (zh) * | 2021-04-19 | 2023-06-02 | 北京阳光诺和药物研究股份有限公司 | 一种阿卡波糖口崩片及其制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3134591A1 (de) * | 1981-09-01 | 1983-03-10 | Bayer Ag, 5090 Leverkusen | Neue arzneimittelpraeparationen fuer glykosidhydrolasen-inhibitoren |
JPH10182687A (ja) * | 1996-10-21 | 1998-07-07 | Bayer Yakuhin Kk | アカルボースの貯蔵安定化法 |
DE19802700A1 (de) * | 1998-01-24 | 1999-07-29 | Bayer Ag | Verfahren zur Herstellung einer im Mund schnell zerfallenden Arzneiform, die als Wirkstoff Acarbose enthält |
US20040081697A1 (en) * | 1998-11-12 | 2004-04-29 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
KR100682836B1 (ko) * | 2004-12-06 | 2007-02-15 | 엘지전자 주식회사 | 유기 전계 발광 소자 |
US20060229261A1 (en) * | 2005-04-12 | 2006-10-12 | John Devane | Acarbose methods and formulations for treating chronic constipation |
MY157620A (en) * | 2006-01-31 | 2016-06-30 | Cytochroma Dev Inc | A granular material of a solid water-soluble mixed metal compound capable of binding phosphate |
JP4931907B2 (ja) * | 2006-02-27 | 2012-05-16 | パナソニック株式会社 | ウェアラブル端末、および、携帯撮像収音装置、およびそれらを実現する装置、方法、プログラム |
FI20070521L (fi) * | 2006-11-10 | 2008-05-11 | Atacama Labs Oy | Rakeita, tabletteja ja rakeistusmenetelmä |
CN101411715B (zh) * | 2007-10-19 | 2012-03-28 | 杭州华东医药集团生物工程研究所有限公司 | 含有阿卡波糖的药物组合物 |
JP5291324B2 (ja) * | 2007-11-01 | 2013-09-18 | 沢井製薬株式会社 | 口腔内崩壊錠 |
JP2009114113A (ja) * | 2007-11-06 | 2009-05-28 | Nipro Corp | 口腔内崩壊錠及びその製造方法 |
EP2231126A2 (en) * | 2007-12-08 | 2010-09-29 | Bayer Schering Pharma Aktiengesellschaft | Oral dispersable tablet |
CL2008003827A1 (es) * | 2007-12-21 | 2009-07-24 | Aptalis Pharmatech Inc | Composicion para tabletas de desintegracion oral que comprende al menos una droga ( temazepam), 0,5-3% de un polimero aglutinanete para odt, un alcohol de azucar y/o sacarido, y un desintegrante; metodo para prepararla; util para tratar una enfermedad o condicion como un trastorno del sueño en pacientes con disfagia.. |
RU2519768C2 (ru) * | 2008-06-20 | 2014-06-20 | Мерк Патент Гмбх | Поддающаяся прямому прессованию и быстро распадающаяся матрица таблетки |
-
2011
- 2011-04-26 NZ NZ603199A patent/NZ603199A/en not_active IP Right Cessation
- 2011-04-26 MY MYPI2012700818A patent/MY179724A/en unknown
- 2011-04-26 CN CN201610934162.1A patent/CN106924199A/zh active Pending
- 2011-04-26 CN CN2011800205487A patent/CN102905687A/zh active Pending
- 2011-04-26 KR KR1020127028046A patent/KR101788350B1/ko active IP Right Grant
- 2011-04-26 SG SG2012076147A patent/SG184851A1/en unknown
- 2011-04-26 SI SI201131170A patent/SI2563329T1/sl unknown
- 2011-04-26 WO PCT/EP2011/056587 patent/WO2011134962A2/en active Application Filing
- 2011-04-26 PE PE2012002079A patent/PE20130403A1/es not_active Application Discontinuation
- 2011-04-26 EP EP11716264.4A patent/EP2563329B1/en active Active
- 2011-04-26 MX MX2012012459A patent/MX348865B/es active IP Right Grant
- 2011-04-26 TW TW100114368A patent/TWI556823B/zh not_active IP Right Cessation
- 2011-04-26 BR BR112012027303A patent/BR112012027303A2/pt not_active IP Right Cessation
- 2011-04-26 ES ES11716264.4T patent/ES2623025T3/es active Active
- 2011-04-26 SG SG10201505844WA patent/SG10201505844WA/en unknown
- 2011-04-26 CA CA2797365A patent/CA2797365A1/en not_active Abandoned
- 2011-04-26 US US13/643,929 patent/US20130131003A1/en not_active Abandoned
- 2011-04-26 JP JP2013506633A patent/JP5944378B2/ja active Active
- 2011-04-26 UA UAA201213526A patent/UA111155C2/uk unknown
- 2011-04-26 AU AU2011247642A patent/AU2011247642C1/en not_active Ceased
-
2012
- 2012-10-11 IL IL222368A patent/IL222368B/en active IP Right Grant
- 2012-10-25 CU CU2012000152A patent/CU20120152A7/es unknown
- 2012-10-26 CO CO12192234A patent/CO6640213A2/es not_active Application Discontinuation
- 2012-10-26 DO DO2012000277A patent/DOP2012000277A/es unknown
- 2012-10-26 CL CL2012003011A patent/CL2012003011A1/es unknown
- 2012-10-26 GT GT201200290A patent/GT201200290A/es unknown
- 2012-10-26 EC ECSP12012279 patent/ECSP12012279A/es unknown
- 2012-10-26 CR CR20120548A patent/CR20120548A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2012003011A1 (es) | Comprimido de desintegracion por via oral que contiene un 1-30 % de acarbosa, un 40-90 % de un vehiculo soluble en agua y un 1-50 % de un vehiculo soluble en agua, para el tratamiento de diabetes mellitus; y procedimiento para preparar comprimidos de desintegracion oral que contienen acarbosa. | |
CL2013001104A1 (es) | Composicion farmaceutica que comprende un inhibidor de sglt2 y una insulina; y uso para tratar una enfermedad o afeccion tal como diabetes mellitus, diabetes mellitus tipo 1 y 2, entre otras. | |
IL223783B (en) | Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine | |
UY33025A (es) | Composicion farmaceutica que comprende un agonista de glp-1 metionina | |
CL2008003116A1 (es) | Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras. | |
NI201200074A (es) | Composición farmacéutica que comprende un agonista de glp-1, una insulina y metionina. | |
CL2012002944A1 (es) | Compuestos derivados de amino-pirimidinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras. | |
CL2012002945A1 (es) | Compuestos derivados de amino-piridazinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras. | |
BRPI1006825A2 (pt) | compostos pró-neurogênicos | |
CL2012003053A1 (es) | Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad. | |
RS55378B1 (sr) | Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2 | |
CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. | |
DK3045164T3 (da) | Vandige farmaceutiske sammensætninger, der indeholder borat-polyol-komplekser | |
AP2011005857A0 (en) | Tablets for combination therapy. | |
EA201071204A1 (ru) | Применение дронедарона для приготовления лекарственного средства для применения в предотвращении госпитализации в кардиологическое отделение или смертности | |
CL2011002041A1 (es) | Compuestos derivaados de 4-isopropilfenilglucitol, inhibidores de sglt1; preparacion farmaceutica; y su uso como agente para mejorar la hiperglucemia posprandial y como agente profilactico o terapeutico para la diabetes. | |
BR112012032008A2 (pt) | anticorpos s100a4 e usos terapêuticos do mesmo | |
CL2012003523A1 (es) | Método para la preparación de una composición farmacéutica que contiene un portador de oxígeno termoestable; composicion farmaceutica que contiene un portador de oxigeno altamente purificado y termoestable. | |
ECSP11011558A (es) | Nuevos compuestos químicos. | |
BRPI0907916A2 (pt) | Heterociclos espirociclos, medicamentos contendo esses compostos, e processos para preparar os mesmos | |
MX344846B (es) | Combinacion de granulos cargados activos con activos adicionales. | |
CL2013000310A1 (es) | Compuestos derivados de tetrahidrofuranilo disustituidos y sus sales, como antagonistas del receptor b1 de bradiquinina; medicamento que contiene a dichos compuestos; su procedimiento de preparacion, util para el tratamiento agudo o profilactico de dolores agudos, osteoartritis, asma, alergias, entre otras enfermedades. | |
CL2015000857A1 (es) | Una composicion farmaceutica que consiste en una primera capa que comprende metformina y una segunda capa que comprende gemigliptina; su metodo de preparacion, util para la prevencion y el tratamiento de la diabetes. | |
BR112013018738A2 (pt) | novos derivados de tetrahidroquinolina | |
IL218008A (en) | Dexbinol or its salt for non-melanoma cancer suppression, its use in the preparation of non-melanoma cancer suppressant, and a pharmacological preparation containing the said |